TC BioPharm Shifts Focus to FDA Clinical Trials

Rhea-AI Summary

TC BioPharm (NASDAQ: TCBP) announced a strategic shift toward FDA trials for its TCB-008 therapy targeting acute myeloid leukemia (AML). The company plans to submit a protocol for a Phase 1b safety trial in Q3 2023, followed by additional IND submissions by early 2024. The study aims to include approximately 9 patients, focusing on dose escalation. CEO Bryan Kobel emphasized the importance of U.S. trials to align with their long-term goal of becoming a commercial leader in oncology. This approach aims to simplify operations, improve economic efficiency, and leverage the substantial AML patient pool in the U.S., potentially leading to rapid trial enrollment.

AI-generated analysis. Not financial advice.

Positive

• Focus on FDA trials for TCB-008 could enhance market positioning.
• Expected rapid enrollment due to significant AML patient pool in the U.S.
• Partnership with MD Anderson is likely to support clinical development.

Negative

• None.

News Market Reaction – TCBP

-9.74%

1 alert

-9.74% News Effect

On the day this news was published, TCBP declined 9.74%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to explore US IND pathway for additional combination trials

EDINBURGH, Scotland, March 7, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that the company has taken steps to focus its clinical strategy on the planned future FDA trials for TCB-008 in AML as a monotherapy and other oncology indications in combination with additional assets.

The pending protocol submission will be a Phase 1b safety trial, with a relatively small patient population and a short timeline to completion. In conjunction with refocusing the clinical team's efforts on the USA, the Company intends to file the first IND in the third quarter of 2023 with an expected additional IND to be filed in the fourth quarter or early 2024.  At this juncture, the Company is anticipating a dose escalating study of approximately 9 patients with an expansion cohort at the optimal dose.

"Our business development efforts over the last 12 months have generated multiple research collaborations and strategic relationships, the majority of which are US based and beginning to come to fruition," said Bryan Kobel, Chief Executive Officer.  "Prioritizing US trials realigns us with our long term goal of becoming a leading commercial stage company, with a myriad of oncological treatment applications for TCB-008 (Omnimmune™) as both a monotherapy and as a combination therapeutic. We firmly believe in the potential of our asset and  the best way to position the Company for success is to commence with this proposed US trial protocol and to pursue future trials through the FDA pathways. Our partnership with MD Anderson will be valuable, both for this study and future FDA trials,  and I anticipate that we're now better positioned for near term success and sustainability, including potentially multiple data readouts in 2024."

TC BioPharm expects this US clinical trial enrollment to be relatively rapid due to the the fact that America offers a significantly greater pool of patients with more than 20,000 AML diagnoses each year. This transition will allow TC BioPharm to become more economically efficient by simplifying its strategy and reducing manufacturing and production efforts.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma-delta T cells and owns our manufacturing facility to maintain cost and product quality controls.

Forward Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

View original content:https://www.prnewswire.com/news-releases/tc-biopharm-shifts-focus-to-fda-clinical-trials-301764501.html

SOURCE TC BioPharm

FAQ

What is TC BioPharm's new focus regarding TCB-008?

TC BioPharm is shifting its focus to FDA clinical trials for TCB-008, primarily targeting acute myeloid leukemia (AML).

When will TC BioPharm submit its IND application?

The first IND application is expected to be submitted in the third quarter of 2023.

What is the expected patient population for the upcoming trial?

The upcoming Phase 1b trial aims to include approximately 9 patients.

How does TC BioPharm plan to streamline its operations?

The company plans to simplify its strategy, which could enhance economic efficiency and reduce production efforts.

What are the anticipated outcomes of the trials for TCB-008?

The trials are expected to provide critical data that could position TC BioPharm for future success and commercial opportunities.